Plant-Derived Natural Products Ameliorating Hypertension via Signaling Pathways: A Review

Yushen Feng1,2,3, Juan Zhou1, Min Zhong1

  • 1Anhui Province Key Laboratory of Non-Coding RNA Basic and Clinical Transformation (Wannan Medical College), Central Laboratory, Yijishan Hospital of Wannan Medical College, Wuhu, China.

Insights

Natural products show promise for managing hypertension, a widespread condition affecting over a billion people. Research highlights flavonoids, terpenoids, and alkaloids as potential antihypertensive agents targeting key disease pathways.

Area of Science:

  • Pharmacology and Natural Product Chemistry
  • Cardiovascular Disease Research
  • Integrative Medicine

Background:

  • Hypertension affects over one billion people globally, increasing cardiovascular disease risk.
  • Essential arterial hypertension is a major risk factor for stroke, renal failure, cardiac hypertrophy, and heart failure.
  • Existing antihypertensive drugs are insufficient for many patients, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To review natural products (NPs) with potential antihypertensive activities published between 2019 and 2024.
  • To identify and categorize NPs targeting key hypertension pathogenesis pathways.
  • To assess the potential of NPs as a source for novel antihypertensive agents.

Main Methods:

  • Systematic literature search of PubMed and Web of Science databases.
  • Inclusion of studies on NPs with antihypertensive potential published from 2019 to 2024.
  • Categorization of identified NPs based on structural frameworks (flavonoids, terpenoids, alkaloids, plant extracts).

Main Results:

  • Seventy unique natural products with potential antihypertensive activity were identified.
  • NPs were classified into flavonoids (20), terpenoids (24), alkaloids (17), and plant-derived extracts (9).
  • These compounds target pathways including oxidative stress, inflammation, vascular remodeling, and neurohormonal signaling.

Conclusions:

  • Natural products offer a promising avenue for developing new antihypertensive therapies.
  • Future research should focus on NPs with dual antioxidant/anti-inflammatory properties and improved delivery systems.
  • Interdisciplinary approaches, including synthetic biology, are crucial for scalable NP production.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
Neural Regulation of Blood Pressure01:18

Neural Regulation of Blood Pressure

The neural regulation of blood pressure involves intricate interactions between the autonomic nervous system (ANS) and cardiovascular system, ensuring adequate perfusion of tissues. This regulation primarily occurs through baroreceptor and chemoreceptor reflexes, involving both short-term and long-term mechanisms.
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
9.1K
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
7.9K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.8K